Bayer shares rise after Q2 earnings beat, guidance raised despite litigation hit

Published 01/08/2025, 08:50
© Reuters.

Investing.com -- Bayer AG (ETR:BAYGN) shares rose on Friday after the German pharmaceutical and biotechnology company reported stronger-than-expected second-quarter earnings and raised its full-year guidance, despite booking €1.7 billion in additional litigation provisions.

Second-quarter EBITDA before special items reached about €2.1 billion, exceeding Jefferies’ forecast of €1.8 billion and the consensus estimate of €1.9 billion. 

Core EPS came in at €1.23, ahead of Jefferies’ €0.65 estimate and 62% above consensus. Compared with the same quarter last year, EBITDA declined 1%, while core EPS increased 31%.

The company lifted its full-year FX-adjusted EBITDA forecast to a range of €9.2 billion to €9.7 billion, compared with €9.1 billion previously. 

FX-adjusted core EPS guidance was raised to €4.45 to €4.95, up from €4.39. Revenue guidance remains unchanged at €44 billion to €46 billion.

The Crop Science division led the operational beat. EBITDA reached €700 million, 55% above Jefferies’ estimate and 33% higher than consensus. Sales in the segment rose 2.2% on a currency- and portfolio-adjusted basis, short of the 3% forecast.

Pharmaceuticals delivered 0.6% growth in adjusted sales, outperforming expectations of a 2% decline. 

EBITDA in the unit was €1.1 billion, slightly below Jefferies’ forecast of €1.172 billion and down 17% from the prior year.

Consumer Health underperformed on the top line, with sales growing 0.2% against a 3.5% estimate. EBITDA for the unit totaled €300 million, 6% below the estimate and 4% lower year over year.

Litigation provisions rose by €1.7 billion, including €1.2 billion related to glyphosate legal costs and €530 million for PCB claims. 

Bayer (OTC:BAYRY) reported 61,000 outstanding glyphosate cases. The total litigation charge amounts to approximately €1.70 per share.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.